Business Advisory services                  Life Sciences Consulting                  Product Development                  ANDAs                  FTFs                  505 b 2 a                  Late Stage Assets                  Phase-II Trials                  Marketing Authorizationís                  Dossiers                  Site Transfers                  Scale ups                   Tail End Brands                  Technologies and Know-how                  Project Management                   Business Excellence & Six Sigma
A US-based pharmaceutical development company had attempted to interest larger pharmaceutical companies in its lead compound, a new molecular entity indicated in a specialty therapeutic area. The company had experienced difficulties in gaining access to decision makers within the targeted companies, and in communicating the benefits of the compound, effectively.
Garphi and its associate companywere asked to take over the licensing initiative. Garphi with the help of its associateredrafted the non-confidential and confidential documents in order to focus on the anticipated benefits of the compound. Garphi then established contact with several companies who had earlier declined interest, and reintroduced the opportunity.
As a result, the small pharmaceutical company signed agreements with 2 mid-sized specialty pharma companiesfor European and Asian rights. The product is currently undergoing Phase III trials and should be launched by both the licensees by 2014.